Search results
Results From The WOW.Com Content Network
In September 2019, Adverum announced six-month data from the first cohort of its phase I trial. [12] The stock price dropped 50% due to investor concerns over deterioration of vision that these trial subjects suffered, as well as several reports of occular inflammation. [12] In June 2020, Laurent Fischer replaced Patterson as CEO of Adverum. [13]
For premium support please call: 800-290-4726 more ways to reach us
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, [2] and Morges, Switzerland. [3] The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 [4] and Incyte Genomics, Inc. of Delaware. [5]
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
Yahoo Finance is a media property that is part of the Yahoo network. It provides financial news, data and commentary including stock quotes , press releases , financial reports , and original content.
For premium support please call: 800-290-4726 more ways to reach us
Adverum is evaluating its novel gene therapy candidate, ADVM-022, designed as a one-time, intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD).[3] and diabetic macular edema (DME) .